Last reviewed · How we verify

NCT04357314: MODIF

Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study

Completed Last updated 19 August 2020
What this trial tests

trial in Myocardial Infarction in 6,332 participants. Completed in 31 May 2020.

Timeline
1 March 2020
Primary endpoint
31 May 2020
31 May 2020

Quick facts

Lead sponsorFrench Cardiology Society
StatusCompleted
Study typeOBSERVATIONAL
Enrollment6,332
Start date1 March 2020
Primary completion31 May 2020
Estimated completion31 May 2020
Sites1 location across France

Conditions studied

Sponsor

French Cardiology Society

Who can join

18 and older, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.
    Bonnet G, Panagides V, Becker M, Rivière N, et al · · 2021 · cited 20× · PMID 33926830 · DOI 10.1016/j.acvd.2021.01.005

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

Other French Cardiology Society trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04357314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing